Therefore, the present study was designed, firstly to explore the molecular protective mechanism of VD3 and its antioxidant and anti-inflammatory effects against TAA-induced hepatic fibrosis, and secondly to investigate if CD34 and FGF23 could act as novel fibrotic markers and genetically upregulate or downregulate in hepatic tissue in correlation with the incidence and amelioration of liver fibrosis. This evidence concerns the gene CD34 and Hepatic fibrosis.